ライフサイエンスコーパス: infected person

1 number of secondary infections caused by an infected person).

2 to high-risk countries, or had contact with infected persons).

3 ion and contain the maximum viral load in an infected person.

4 h level, often resulting in the death of the infected person.

5 antibody isolated from an HIV-1 chronically infected person.

6 e sensitive to antibodies in the serum of an infected person.

7 ere 29 588 deaths reported among 145 845 HIV-infected persons.

8 nsive primary CVD prevention strategy in HIV-infected persons.

9 ncy in finding, evaluating, and treating HCV-infected persons.

10 nt HAND or improve cognitive function in HIV-infected persons.

11 topes, revealing new immune responses in HIV-infected persons.

12 included 126 studies describing 491 608 HIV-infected persons.

13 al testing would identify additional 526 HCV-infected persons.

14 n may improve cardiovascular outcomes in HIV-infected persons.

15 ly reduced herpes zoster incidence among HIV-infected persons.

16 ncreased gastric cancer risk among H. pylori-infected persons.

17 philis in human immunodeficiency virus (HIV)-infected persons.

18 target to improve the immune function in HIV-infected persons.

19 estry-specific factor influencing NCI in HIV-infected persons.

20 IV-infected persons when compared to non-HIV-infected persons.

21 -exposed persons and infectiousness of HIV-1-infected persons.

22 is not suitable for all treatment-naive HIV-infected persons.

23 ity among human immunodeficiency virus (HIV)-infected persons.

24 yopathy among asymptomatic Trypanosoma cruzi-infected persons.

25 ansmission and a large reservoir of latently infected persons.

26 HIV-2 ARV susceptibility and treating HIV-2-infected persons.

27 is recommended as preventive therapy in HIV-infected persons.

28 rent outcomes of disease are observed in HIV-infected persons.

29 T) in all human immunodeficiency virus (HIV)-infected persons.

30 settings; and sexual transmission among HIV-infected persons.

31 iated nephropathy (HIVAN) predominate in HIV-infected persons.

32 sional guidance on the use of HCV PIs in HIV-infected persons.

33 iagnosis and initiation of treatment for HIV-infected persons.

34 common in human immunodeficiency virus (HIV)-infected persons.

35 bclinical atherosclerosis progression in HIV-infected persons.

36 tries would miss approximately two-thirds of infected persons.

37 ts for new immune-based interventions in HIV-infected persons.

38 ted availability of samples from acutely HIV-infected persons.

39 that may aid CVD risk stratification in HIV-infected persons.

40 , and testing and treatment for HBV- and HCV-infected persons.

41 ltered in human immunodeficiency virus (HIV)-infected persons.

42 tive in suppressing virus replication in HIV-infected persons.

43 n of primary CD4 T cells from healthy or HIV-infected persons.

44 m the study of VRC01 in the treatment of HIV-infected persons.

45 lity to detect prevalent TB amongst HIV-1 co-infected persons.

46 sponses in a cohort of untreated HIV clade C-infected persons.

47 ndothelial cell inflammation observed in HIV-infected persons.

48 lness among pregnant girls and women and HIV-infected persons.

49 ical to the present and future health of HIV-infected persons.

50 The frontal cortex from 32 HIV-infected persons (12 without evidence HIV-1 encephalitis

51 y larger viral reservoirs than non-subtype B-infected persons (2 infected with subtype CRF01_AE and 3

52 1,571 HIV-1-infected persons (47% women) from nine countries in four

53 nfection, the next great frontier is to cure infected persons, a formidable challenge.

54 ssion without induction of resistance in HIV-infected persons after analytic treatment interruption.

55 Risk of HCC in HCV genotype-3 infected persons after DAA therapy is not well known.

56 biannual viral load monitoring on 2,489 HIV infected persons (age 15+).

57 ons among human immunodeficiency virus (HIV)-infected persons aged 50-64 years have been understudied

58 le similar to the serological profile of HCV-infected persons, although the pathogenicity of this vir

59 ed by direct contact with the body fluids of infected person and objects contaminated with virus or i

60 ny type of oral HPV infection was 34% in HIV-infected persons and 19% in HIV-uninfected persons.

61 Contact with infected persons and contaminated environments are belie

62 Evidence defining treatment for HIV-infected persons and for pregnant women is limited, but

63 ported young ages at cancer diagnosis in HIV-infected persons and have suggested that HIV accelerates

64 ge the use of routine HAV vaccination in HCV-infected persons and its incorporation into clinical pra

65 C virus (HCV) occurs in approximately 30% of infected persons and less often in populations of Africa

66 (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) to

67 d controlled trials of micronutrients in HIV-infected persons and that most trials used high-dose mul

68 ng prevention and care opportunities for HIV-infected persons and their partners.

69 irus epidemic, the risk of GBS in Zika virus-infected persons, and the clinical management of GBS cas

70 Lifetime healthcare costs for an HCV-infected person are significantly higher than for noninf

71 Although most infected persons are asymptomatic, ZIKV has been associa

72 Human immunodeficiency virus (HIV)-infected persons are at a higher risk of severe influenz

73 HIV-infected persons are at greater risk of developing tuber

74 HIV-infected persons are at heightened risk for recurrent co

75 Human immunodeficiency virus (HIV)-infected persons are at higher risk for serious complica

76 Although human immunodeficiency virus (HIV)-infected persons are at increased risk for major cardiov

77 er complications and increased survival, HIV-infected persons are increasingly developing common heal

78 Human immunodeficiency virus type 1 (HIV)-infected persons are more susceptible to tuberculosis th

79 une responses to influenza vaccine among HIV-infected persons are needed.

80 gies to reduce HSV-2 transmission from HIV-1-infected persons are needed.

81 nfluenza vaccine-induced Ab responses in HIV-infected persons are poorly understood.

82 ions are needed, including ensuring that HIV-infected persons are receiving appropriate care and trea

83 Up to 60% of HBV-infected persons are unaware of their infection, and man

84 Most HCV-infected persons are unaware of their status yet are at

85 human immunodeficiency virus type 1 (HIV-1)-infected persons are unknown.

86 Responses in BAL were 15-fold lower in HIV-infected persons as compared to uninfected persons (P =

87 d clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-op

88 virologic response after treatment among HCV-infected persons at any stage of fibrosis is associated

89 surable biomarker to identify populations of infected persons at high risk for gastric cancer.

90 iciency virus (HIV)-negative contacts of HIV-infected persons at increased risk of exposure to infect

91 shows promise as a tool for identifying HIV-infected persons at risk for NCI.

92 atment to project the life expectancy of HIV-infected persons, based on smoking status.

93 ly active human immunodeficiency virus (HIV)-infected persons be tested at least annually for syphili

94 We estimate that 26% of WNV-infected persons become symptomatic, defined by the pres

95 Treating HCV infected persons before development of cirrhosis may red

96 nities for identifying West Nile virus (WNV)-infected persons before symptoms develop and for charact

97 (IRIS) in human immunodeficiency virus (HIV)-infected persons beginning antiretroviral therapy (ART)

98 VDD was highly prevalent in black HIV- infected persons but did not explain the observed racial

99 ing liver disease in hepatitis C virus (HCV)-infected persons, but is a bottleneck to evaluation, fol

100 rapy (ART) reduces the infectiousness of HIV-infected persons, but only after testing, linkage to car

101 ality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking c

102 pulation, and examined differences among HIV-infected persons by RNA level.

103 The same medications used to treat infected persons can also be used by uninfected persons

104 Few human immunodeficiency virus (HIV)-infected persons can maintain low viral levels without t

105 Early diagnosis is imperative so that infected persons can take measures to stay healthy, get

106 %), corresponding to 2.7 million chronically infected persons (CI, 2.2 to 3.2 million persons) in the

107 virin) that enrolled chronic genotype 1a HCV-infected persons coinfected with suppressed HIV: 5 of 6

108 nt-naive, human immunodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cA

109 rading system will maximize the treatment of infected persons compared with a DNA-based test but will

110 HIV-infected persons compared with HIV-uninfected persons we

111 igh frequencies of MDSCs were present in HIV-infected persons, compared with healthy controls.

112 nce of non-HIV cancer risk factors among HIV-infected persons contributes to cancer risk, substantial

113 ic network tracing that starts with recently infected persons could support public health efforts to

114 probability of a false-negative result in an infected person decreases from 100% (95% CI, 100% to 100

115 HIV-infected persons demonstrated a higher frequency of posi

116 HIV/CMV co-infected persons despite prolonged viral suppression oft

117 gnitive disorder (HAND) remain common in HIV-infected persons, despite HAART, but whether anemia pred

118 In contrast, most acutely infected persons detected by the HIV Combo assay demonst

119 rial infections worldwide, and virtually all infected persons develop coexisting gastritis, a signatu

120 (the number of secondary cases caused by an infected person during the infectious period) was 2.12 b

121 represent only one-fifth of about 80 000 HCV-infected persons dying that year, at least two-thirds of

122 ity (ie, touching, feeding, or nursing a NiV-infected person), enabling exposure to droplet infection

123 HBCT is effective at getting HIV-infected persons enrolled in HIV care before they become

124 he full item set was administered to 644 HIV-infected persons enrolled in three ongoing research stud

125 orbid conditions are warranted for older HIV-infected persons, especially older women.

126 stric adenocarcinoma, yet only a minority of infected persons ever develop this malignancy.

127 iple routes including direct contact with an infected person, fecal matter, or vomitus, and contact w

128 Participants included 655 HIV-infected persons followed for up to 6 years in cohort st

129 The apparent cure of an HIV-infected person following hematopoietic stem cell transp

130 o encourage screening and identify and refer infected persons for care by declaring that such interve

131 of the criteria may erroneously exclude HSV-infected persons from a necessary diagnostic test or, al

132 ks work mainly by source control (preventing infected persons from transmitting the virus to others),

133 TS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 i

134 HIV-infected persons >/= 18 years of age who were previously

135 HIV-infected persons had a 10-fold decrease in total TCR rep

136 Forty-six percent of HIV-infected persons had insomnia (PSQI >5), and 30% reporte

137 HIV-infected persons had significantly lower (worse) T score

138 ins on insulin resistance or diabetes in HIV-infected persons has not been assessed within a randomiz

139 ity among human immunodeficiency virus (HIV)-infected persons, has been associated with concurrent ri

140 Infected persons have a high prevalence of infection sev

141 HIV-infected persons have a high prevalence of insomnia, but

142 human immunodeficiency virus type 1 (HIV-1)-infected persons have diminished responses to hepatitis

143 agnostics for cryptococcal meningitis in HIV-infected persons have evolved from culture to India ink

144 Human immunodeficiency virus (HIV)-infected persons have higher rates of herpes zoster than

145 HIV-infected persons have less robust antibody responses to

146 l laboratory indicates that about 1 in 4 HCV-infected persons have levels of liver disease put them a

147 (CVD) is now a leading cause of death in HIV-infected persons; however, risk markers for CVD are ill

148 Cardiovascular disease is common in HIV-infected persons; however, the most common cardiac arrhy

149 ere made based on the household locations of infected persons identified from previous surveys, and e

150 The proportion of infected persons identified through population screening

151 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) w

152 ity rates among human immunodeficiency virus-infected persons in Africa.

153 ng human immunodeficiency virus type 1 (HIV)-infected persons in Africa.

154 rvival of human immunodeficiency virus (HIV)-infected persons in areas where antiretroviral therapy i

155 the first organ transplantation between HIV-infected persons in Canada, we review Canadian law regar

156 ure policy regarding organ donation from HIV-infected persons in Canada.

157 ucted a retrospective cohort study among HIV-infected persons in care at the Comprehensive Care Cente

158 For HIV-infected persons in care during 2000-2010, rates of firs

159 In our study population of HIV-infected persons in care, women had lower baseline hemog

160 id conditions were prevalent among older HIV-infected persons in care; disparities existed by sex.

161 Cancer is the leading cause of death for HIV-infected persons in economically developed countries, ev

162 human immunodeficiency virus type 1 (HIV-1)-infected persons in low-middle income countries, thanks

163 We estimated that there are 1.5 million CHB-infected persons in Shanghai.

164 CrAg screening of HIV-infected persons in the blood prior to development of fu

165 e remains a leading cause of death among HIV-infected persons in the United States and elsewhere.

166 ompared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs

167 ght be applied to a broader community of HIV-infected persons in whom the risks of HSCT currently out

168 Target Population: HIV-infected persons, including future incident cases.

169 imally defined epitopes in 341 untreated HIV-infected persons, including persons who spontaneously co

170 he causes of low bone mineral density in HIV-infected persons, including the impact of specific antir

171 We prospectively studied HCV infected persons initiated on a DAA regimen between Octo

172 of HCV-infected Veterans, we identified HCV-infected persons initiated on PrOD or LDV/SOF, excluding

173 When a recently infected person is identified, family clustering and com

174 nd explain, at least in part, why every HSV1-infected person is not equally likely to develop HSV1-as

175 HAV vaccination of all HCV-infected persons is costly and likely to expose many ind

176 omparison of intra-host viral variants among infected persons is frequently used for tracing transmis

177 primary consideration in treating HCV in HIV-infected persons is the potential for drug interactions.

178 iciency virus (HIV)-specific antibody to HIV-infected persons leads to the development of antibody-re

179 Among infected persons, liver disease awareness was only 15.19

180 In HIV-infected persons, liver fibrosis is associated with disc

181 s directly proportional to the number of HIV-infected persons living in the home for ILI (RR, 1.39; P

182 mon among human immunodeficiency virus (HIV)-infected persons living in tuberculosis-endemic areas, b

183 asymptomatic or pre-symptomatic, and that an infected person may infect 5.6 other individuals on aver

184 ion among human immunodeficiency virus (HIV)-infected persons may contribute to atherosclerosis.

185 n of T-cell subpopulations and that most HIV-infected persons may retain a sufficiently diverse TCR r

186 ination since 1991, offset by numbers of HBV-infected persons migrating to the United States from end

187 Finally, HIV subtype B-infected persons (n = 25) harbored significantly larger

188 In persistently infected persons nAb responses were delayed then progres

189 Helicobacter pylori infection; however, most infected persons never develop this malignancy.

190 D deficiency was not more common among HIV- infected persons, nor did it seem associated with HIV- r

191 Latently infected persons, of which there are estimated to be app

192 RDS identified 4,051 HIV-infected persons, of whom 2,325 (57.4%) were unaware of

193 It also identified 5,777 HCV-infected persons, of whom 5,337 (92.4%) were unaware tha

194 smission through unprotected sex with an HIV-infected person on cART for >6 months.

195 and lipohypertrophy are prevalent among HIV-infected persons on ART.

196 d to assess the benefits of treatment of HCV-infected persons on development of HCC.

197 HIV-infected persons on suppressive antiretroviral therapy (

198 g the V1/V2 domains between Envs of the same infected person or between two persons linked by a trans

199 2000, suggesting late diagnosis of some HIV-infected persons or antiretroviral therapy failure.

200 ing highly variable shedding patterns, in an infected person over time, is poorly understood.

201 vant T helper 1-type responses were found in infected persons, paralleling the studies in animal mode

202 ersons, household and sexual contacts of HBV-infected persons, persons requiring immunosuppressive th

203 safety of organ transplantation between HIV-infected persons prompted a change in US American law to

204 HIV-infected persons reach higher levels of influenza seropr

205 45 529 HIV-infected persons received care in an NA-ACCORD-participa

206 Uninsured and underinsured HIV-infected persons receiving RWHAP assistance were more li

207 number of deaths in hepatitis C virus (HCV)-infected persons recorded on US death certificates has b

208 ld in-tube (QFT) plasma samples in 421 HIV-1-infected persons recruited within the screening and enro

209 ing to high-risk individuals, and 50%-75% of infected persons remain unaware of their status.

210 optimal methods to predict MI risks for HIV-infected persons remain unclear.

211 tbreak of variant influenza, the majority of infected persons reported exposures, suggesting that swi

212 Only 18% of HIV-infected persons reported using a sleep medication at le

213 atent tuberculosis infection (LTBI) of HIV-1-infected persons represents a challenge in TB epidemic c

214 not accommodate the increased number of HIV-infected persons requiring care.

215 an increase in T cells in the airways in HIV-infected persons resulted in the overall number of M. tu

216 t of acute HCV genotype-1 infection in HIV-1-infected persons results in a high relapse rate.

217 This article documents cancer risk among HIV-infected persons, reviews immune system effects of HIV i

218 HIV-infected persons should be managed and monitored for all

219 ologic checkpoint inhibitor in healthy HIV-1-infected persons, single low-dose BMS-936559 infusions a

220 igen-specific CD4 T cells in a cohort of HIV-infected persons starting antiretroviral treatment (ART)

221 Longitudinal analysis of chronically infected persons starting ART revealed that the frequenc

222 ation with lower CD4 and higher VL among HIV-infected persons, suggesting that immune dysfunction mig

223 Among HCV-infected persons, SVR was associated with reduced risk f

224 FT-GIT, 52% [95% CI, 41%-62%]) and among HIV-infected persons (T-SPOT, 52% [95% CI, 40%-63%]; QFT-GIT

225 k population for HCV RNA might identify more infected persons than routine testing for HCV antibodies

226 mely studies that estimate the proportion of infected persons that seek care are needed to improve th

227 Interestingly, in one dual-infected person, the neutralizing response to HSV-2 was

228 Among HIV-infected persons, the risk of death by year 3 was 3% in

229 -risk equation, and 1 model developed in HIV-infected persons: the Data Collection on Adverse Effects

230 aces contaminated with droplets generated by infected persons through exhaling, talking, coughing and

231 Identification of hepatitis C virus (HCV)-infected persons through screening could lead to interve

232 iciently identifying a maximum number of HIV-infected persons through voluntary HIV testing and initi

233 ty in a cross-sectional comparison of 19 HIV-infected persons to 18 HIV-uninfected controls.

234 A patient navigator linked 97% of infected persons to care.

235 term morbidity and mortality by predisposing infected persons to cirrhosis of the liver and liver can

236 unity in strategic milieus, predisposing HIV-infected persons to complications of acute or chronic in

237 immunodeficiency virus (HIV) evolves within infected persons to escape being destroyed by the host i

238 recommend ART as soon as possible in all HIV infected persons to reduce the risk of disease progressi

239 increasing prevalence of osteoporosis in HIV-infected persons translates into a higher risk of fractu

240 ith anemia and its effect on survival in HIV-infected persons treated with modern combined antiretrov

241 ion during 1 unprotected sex act with an HIV-infected person under combination antiretroviral therapy

242 iviral activity of UB-421 monotherapy in HIV-infected persons undergoing analytic treatment interrupt

243 HIV-infected persons undergoing organ transplantation genera

244 s progression, and HCC development among HCV-infected persons using the Electronically Retrieved Coho

245 protease inhibitors (PIs) prescribed to HIV-infected persons variably modulate cathepsin activities

246 In 2009 a 28-year-old HIV-infected person was estimated to have 45.4 years of life

247 ed tuberculosis or death by year 3 among HIV-infected persons was 4% in the intervention group and 5%

248 ion-level viral suppression among 15,399 HIV-infected persons was 42% at baseline and was higher in t

249 mortality risk in HAV superinfection of HCV-infected persons was 7.23 (95% confidence interval: 1.24

250 ss of liver disease and treatment rate among infected persons was dismal.

251 The IMD incidence in HIV-infected persons was higher for all age categories, with

252 including studies reporting mortality in HCV-infected persons was performed.

253 nef quasispecies from nine chronically HIV-1-infected persons were examined for sequence evolution an

254 Most infected persons were immunocompromised.

255 Infected persons were more likely to be aged 40 to 59 ye

256 antiretroviral-treated, immune-restored, HIV-infected persons when compared to non-HIV-infected perso

257 antiretroviral-treated, immune-restored, HIV-infected persons when compared with HIV-uninfected perso

258 HIV-infected persons who achieve undetectable viral loads on

259 se the proportion of hepatitis C virus (HCV)-infected persons who know their status and are linked to

260 It has been suspected that infected persons who remain asymptomatic play a signific

261 HIV-infected persons who were aged 45-65 years, had a plasma

262 e (both MSM and PWID), the prevalence of HIV-infected persons who were unaware of their status increa

263 A hepatitis C virus (HCV)-infected person will ideally have access to quality heal

264 patient is the first reported case of an HIV-infected person with dual Balamuthia mandrillaris and Ac

265 cause of higher susceptibility, because HIV-infected persons with a high peripheral CD4(+) T-cell co

266 Routine vaccination of HIV-infected persons with a quadrivalent meningococcal conju

267 imated proportion of hepatitis C virus (HCV)-infected persons with advanced fibrosis or cirrhosis is

268 fic CD4(+) T cell responses in untreated HIV-infected persons with and without neutralizing antibodie

269 ion among human immunodeficiency virus (HIV)-infected persons with antiretroviral therapy (ART)-assoc

270 cells were relatively well maintained in HIV-infected persons with aTB, despite severe immunodeficien

271 lic and health care providers and linkage of infected persons with care and treatment services can in

272 cal guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 x 10(9

273 ce on the effectiveness of treatments in HIV-infected persons with CD4 counts greater than 0.200 x 10

274 inant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and

275 Treatment of African HSV-2/HIV-1-infected persons with daily suppressive acyclovir did no

276 the use of a single dose of BPG to treat HIV-infected persons with early syphilis.

277 fail to identify substantial numbers of HIV-infected persons with elevated CVD risk who could potent

278 HIV-infected persons with high VACS Index scores are at incr

279 s not associated with insomnia; however, HIV-infected persons with insomnia were 3.1-fold more likely

280 n interpreting absolute CD4(+) counts of HIV-infected persons with known or suspected liver disease,

281 Projected 5-y survival in HIV-infected persons with LAB-CD4 is 60.9% (95% CI, 60.9%-61

282 portional hazard ratios for mortality in HIV-infected persons with lung disease during the HAART era.

283 HIV-infected persons with multiple anal HPV types or a nadir

284 Our results indicate that HIV-infected persons with neutralizing antibodies have signi

285 ciency may attenuate disease among H. pylori-infected persons with no response to antibiotics.

286 The long-term survival of HIV-infected persons with symptomatic cryptococcal meningiti

287 y when treating human immunodeficiency virus-infected persons with syphilis.

288 e associated with increased mortality in HIV-infected persons with tuberculosis.

289 ontrollers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in

290 rsons per day, and the detection rate of HIV-infected persons with viremia (regardless of their aware

291 We show that HIV/CMV co-infected persons with virologic suppression and recovere

292 idence of non-AIDS-defining events among HIV-infected persons with virological suppression should con

293 AD was positive for 5.1% of asymptomatic HIV-infected persons, with higher rates among those with nas

294 low incidence of liver-related deaths in HIV-infected persons without HCV or HBV coinfection.

295 autophagy was observed in the brains of HIV-infected persons without HIV-1 encephalitis compared wit

296 s of autophagy compared with brains from HIV-infected persons without HIV-1 encephalitis or HIV-uninf

297 aria transmission, in Africa many falciparum-infected persons without smear-detectable gametocytes st

298 achieve 73% virologic suppression among HIV-infected persons worldwide by 2020.

299 o meet the critical goal of treating all HIV-infected persons worldwide, there is movement toward ext

300 ll incidence rate of 0.74 cases per 1000 HIV-infected person-years (95% confidence interval, 0.43-1.0